Blood protein predictors of brain amyloid for enrichment in clinical trials?

BACKGROUND: Measures of neocortical amyloid burden (NAB) identify individuals who are at substantially greater risk of developing Alzheimer's disease (AD). Blood-based biomarkers predicting NAB would have great utility for the enrichment of AD clinical trials, including large-scale prevention t...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Alzheimers Dement (Amst)
Autores principales: Ashton, Nicholas J., Kiddle, Steven J., Graf, John, Ward, Malcolm, Baird, Alison L., Hye, Abdul, Westwood, Sarah, Wong, Karyuan Vivian, Dobson, Richard J., Rabinovici, Gil D., Miller, Bruce L., Rosen, Howard J., Torres, Andrew, Zhang, Zhanpan, Thurfjell, Lennart, Covin, Antonia, Hehir, Cristina Tan, Baker, David, Bazenet, Chantal, Lovestone, Simon
Formato: Artigo
Lenguaje:Inglês
Publicado: Elsevier 2015
Materias:
Blood-Based Biomarker
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4876903/
https://ncbi.nlm.nih.gov/pubmed/27239491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.dadm.2014.11.005
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares